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                                      INTRODUCTION 
 Anogenital warts have been recognized as a disease entity for 
many centuries. They were recognized by early Greek and Roman 
physicians such as Hippocrates and Galen. The term Condyloma was 
derived from ancient Greek word meaning “a round swelling adjacent 
to the anus”. The addition of the suffix acuminate is a relatively new 
feature, appearing towards the end of the 19th century. The viral etiology 
for development of human skin warts were proposed in the early 20th 
century1 and viral particles were seen on electron microscopy of wart 
samples in the late 1960s2. Gissman and Zur Hausen3, isolated HPV 6 
from genital wart in 1980. Cautery was used as a treatment from 6th 
century onwards. Genital wart as a manifestation of HPV infection 
represents the tip of the iceberg when considering the total spectrum of 
infection. Within the spectrum of sub clinical infection there are several 
distinct entities. True prevalence of HPV anogenital infection in the 
community is not known. Current evidence suggests that over 50% of 
sexually active adults have been infected with one or more HPV types. 
Progress in HPV research was hampered by the inability to culture the 
virus in vitro and absence of satisfactory animal models. Major 
advances in molecular, biological techniques such as DNA amplification 
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and splicing, have in part overcome the problem in detection of Human 
Papilloma Virus infection. Many patients do not seek medical 
help.Although most anogenital wart in immunocompetent patient 
eventually undergoes spontaneous regression, treatment is offered to the 
majority of affected individuals  to reduce the risk of secondary 
infection and to alleviate anxiety . Immunocompromised state alters the 
natural course of HPV infection. And increased incidence of genital 
wart and persistence of HPV infection is seen. Certain HPV types have 
been implicated in the causation of benign and malignant cancerous 
anogenital disease as well as benign and malignant head and neck 
lesions. Bearing in mind that carcinomas are considered and recorded as 
a sexually transmitted disease, according to the World Health 
Organization, its determination and the application of the respective 
therapeutic concepts according to the location and dimensions of the 
lesions is of paramount importance for the patient's prognosis.    
Papilloma viruses are difficult to reproduce under in vitro conditions, so 
generation of a "normal” vaccine is impossible. Hence virus-like 
particles (VLP), which are recombinant versions, are used as vaccine 
presently. 
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REVIEW OF LITERATURE 
DEFINITION  
            Anogenital wart is a benign proliferation of skin and mucosa of 
anus, genitalia and its adjoining area by Human Papilloma Virus, 
subtypes 6 and 11 in >90% of the cases. These viruses infect 
differentiating epithelial cells of skin and mucosa. Patients with visible 
warts may be infected simultaneously with oncogenic “high risk” HPVs 
such as types 16 and 18, which mostly give rise to subclinical lesions 
associated with intraepithelial neoplasia (IN) and anogenital cancer.    
EPIDEMIOLOGY            
Genital warts as a manifestation of HPV infection represent the 
tip of the iceberg when considering the total spectrum of infection. 
Within the spectrum of sub clinical infection there were several distinct 
entities namely, acetowhite epithelium, macroscopically normal 
epithelium but with cytological or histological evidence of HPV 
infection such as koilocytes  and finally macroscopically and 
microscopically normal epithelium in which HPV had been detected by 
Hybridization technique or by DNA amplification by PCR. 
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True prevalence of HPV anogenital infection in the community is 
unknown because 
• Many patients do not seek medical help. 
• Symptomless and subclinical infections are common. 
• Most cases are diagnosed after the appearance of 
condylomata. 
• Many individuals with genital wart consult general 
practitioners, who fail to notify these cases to public health 
authorities. 
      Current evidence suggests that over 50% of sexually active adults 
have been infected with one or more HPV types. Infection rates vary 
and depend on the quantity of virus particles, types,intensity,length of 
contact and also on the patient's immunity status. In United States, 
estimated prevalence of genital warts among men and women between 
15 -49 years of age is 1.4 million and 19 million respectively. In Britain 
and Ireland 80000 new cases of anogenital warts are reported annually. 
HPV prevalence estimates for women in countries around the world 
range from 2% to 44% whereas among males it ranges from 2.3% to 
34.8%. Prevalence of genital warts in India has been reported to be 5.1% 
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to 25.2% of STD patients57-59. Incidence of anogenital warts has 
increased from 7.2% to 8.8% among the HIV infected patients over a 
period of 5 years60.  
HPV after entry may remain dormant without producing any 
lesion or may produce symptomatic or asymptomatic lesions. 
Symptomatic lesions appear after an incubation period of 1 to 8 months 
with an average of 3 months. Rarely do they resolve spontaneously 
without any treatment. 
MORPHOLOGY OF HPV 
HPV belongs to the Family of Papillomaviridae, formerly 
members of the Papovaviridae family. The following five genera contain 
members that infect humans who are highly host specific Alpha, Beta, 
Gamma, Mupa and Nupapapillomavirus. 
HPV Virion is non enveloped and are composed of 72 pentameric 
capsomeres forming outer coat. This coat consists of major and minor 
capsid proteins. These are arranged on a skewed icosahedral lattice. The 
capsids are approximately 60 nm in diameter. 
The genome is double stranded, super coiled, circular DNA of 7.2 
Kilo bases, composed of approximately 8000 nucleotide base pairs. It  
13 
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Consist of 3 regions, namely Early region (E1-E7), Late region 
(L1 & L2), Upstream Regulatory region (URR) or Long Control 
Region(LCR). 
           The early regions encode for proteins that are involved with the 
regulation of viral DNA replication and transcription, where as late 
region encodes as L1 and L2 for major and minor and capsid proteins 
respectively.  
           Early genes (E6, E7) are involved in oncogenic transformation in 
high risk HPV types4, 5.  
The HPV are epithileotropic and their replication depends on the 
presence of differentiating squamous epithelium. The capsule proteins 
and infectious viruses are found in the superficial differentiated cell 
layers.  
The use of Raft culture system which forms the stratified 
squamous epithelium has now produced limited amount of infectious 
HPV. Of more than 200 types, 45 types can infect genital epithelium. 
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TABLE 1: FUNCTIONS OF EARLY AND LATE GENES 
GENE FUNCTION 
E1 Initiation of DNA replication 
E2 Transcriptional regulation/DNA replication 
E3  
E4 Disrupts cytoskeleton 
E5 Transforming protein, interacts with growth factor 
receptors 
E6 Transforming protein, binds to p53, leading to 
degradation 
E7 Transforming protein, binds to pRB 
LCR Early  promoter, transcriptional regulatory motifs.  
L1 Major capsid protein 
L2 Minor capsid protein 
 
TYPES OF HPV 
Cutaneous (nongenital) types  :  HPV 1, 2, 3 and 4  
Genital-mucosal types               :  HPV 6 (a-f), 11 (a & b), 16, and 18 
Those isolated from EV          :   HPV 5 and 8 (>20 types) 
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TABLE 2: HPV TYPES AND CLINICAL DISEASE6 
CLINICAL DISEASE HPV TYPES (FREQUENT) 
Condylomata acuminata  6, 11 
Cervical intraepithelial neoplasia  
Low grade  6, 11 
High grade                                             16, 18 
Bowenoid papillosis   16 
Cervical cancer  16, 18 
Giant condyloma of bushke and 
Lowenstein 
6, 11 
Other verrucous carcinomas  
Oral and laryngeal papilloma                 6, 11 
In HIV patients 7,72,73 
 
TRANSMISSION OF HPV VIRUS: 
• Genital HPV infection is transmitted primarily through sexual 
contact. The infectivity of HPV infection between sexual partners 
is estimated to be about 60%. During the sexual act, micro 
abrasions occur in male and female genitalia and anus in 
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homosexuals; through this micro abrasion transfer of HPV virions 
from the epithelial cells of infected partner to the basal layer of 
recipient occurs.  
• Auto-inoculation by Digital transmission and adjacent contiguous 
epithelium8. 
• Vertical (Perinatal) transmission has been observed in infants 
born to women with genital wart during pregnancy. These infants 
develop laryngeal papilloma and congenital condylomas9.  
• HPV virus is neither blood-borne nor is transmitted by fomites. 
• Smoking tobacco may also be a risk factor for the development of 
genital wart. But this association is uncertain7.          
PATHOGENESIS10, 11  
Inoculation of virus into the epithelium occurs through abrasions 
after sexual contact with HPV infected individuals. Inoculated virus 
infects basal cells through binding with α6 integrin and laminin 
receptors .Cell surface heparan sulfate binds HPV particles with high 
affinity followed by Clathrin/caveolin mediated endocytosis. HPV 
genome gets incorporated into differentiating cells of the epidermis. The 
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integration of viral proteins in human cells disturbs cellular homeostasis. 
The expression of E6 and E7 genes leads to immortalization of 
keratinocytes and stimulates cellular proliferation. HPV DNA replicates 
as cell differentiation occurs. Capsid proteins are synthesized in the 
upper layer of the epidermis and assembled into virion. Viral particles 
are then shed from the lesions.  
IMMUNOLOGY 
Both cell mediated immunity (CMI) and humoral immunity 
develop against human papilloma viral infection. 
HUMORAL IMMUNITY 
“One way cross reactivity” 12: The cutaneous warts are auto 
inoculable on to genital mucosa, but genital warts are not able to 
produce infection on to glabrous skin. These differences are seen not 
only to their infectivity but also serologically. Antibodies against 
cutaneous warts reacts not only to antigen of cutaneous wart, also reacts 
to antigen of genital warts. But antibodies against genital warts react 
only to antigen of genital wart. Almedia analyzed that only 50% of 
patients had demonstrable antibody. No particular correlation between 
presence of antibody, types and duration of lesions were seen, but 
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recurrences occur due to absence of antibodies. Antibodies produced 
against L1 protein i.e capsid antigen, are type specific and act as 
neutralizing antibody which prevents recurrences. The median time to 
seroconversion is approximately one year and antibodies persist for 
decades. In regressing warts, IgM (100%), IgG (97%) and IgA (80%) 
classes of antibody to HPV were detected. The cure rate was high when 
complement fixing antibodies (CF) IgG antibodies were seen in the 
serum. In the absence of CF antibodies, healing process occur slowly. 
Increasing titre of circulating antibodies has been demonstrated in 
regressing warts.       
CELL MEDIATED IMMUNITY 
  CMI plays a major role in both elimination and prevention of 
recurrence of infection. Histopathology of Spontaneous regression of 
wart shows stromal edema and a dense sub epithelial and epithelial 
infiltrate of T lymphocytes in which CD4+ cells out number CD8+ 
cells15,16. Prominent infiltration of macrophages in the stroma are seen16. 
These infiltrating cells have increased expression of CD25 (α chain of 
interleukin 2 receptor) and HLA DR. The majority of T cells express 
CD45RO isoform but 10-15% CD 45RA isoform are also expressed. 
Keratinocytes in regressing warts shows expression of HLA DR and 
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ICAM-1  result of production of cytokines such as IFN ע and TNFα by 
infiltrating and activated CD4+ cells and macrophages . The endothelial 
cells in the blood vessels of the stroma show up regulation of ICAM-1, 
E-SELECTIN and VCAM-1 which are important in lymphocyte homing 
to site of inflammation. Spontaneous regression of condyloma 
acuminata results from a TH1 type response. 
EVIDENCE FOR ROLE OF CMI 
The role of CMI in genital wart protection is evidenced by the 
increased incidence of genital warts in immunodeficiency patients and 
in Children who showed reduced tuberculin reactivity14. Marked 
mononuclear cell dermal infiltrate in spontaneously resolving lesions is 
a further proof to the role of CMI. 
  Certain  patients  shows  spontaneous  regression  of  warts  but  
others  show persistent of warts which is  due to reduced local immune 
responses. Reduced local responses may be due to presence of Virus 
producing cells which are away from basement membrane (BM), 
inadequate production of viral antigens, Insufficient HLA expression 
and Local inhibitory effect of the primary infected cells to the immune 
system. 
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HPV AND ONCOGENESIS 
  Certain HPV types have been implicated in the causation of 
benign and malignant cancerous anogenital diseases as well as benign 
and malignant head and neck lesions.  
High cancer risk  :  HPV types 16, 18, 45, 31 and 33 
Intermediate cancer 
risk 
: HPV types 30,31,33,35,39,51–
53,56,58,59,66,68,73 and 82 
Low cancer risk  :  HPV types 6, 11, 40, 42–44, 54, 61, 70, 
72 and 81 
The Human Papilloma Viral DNA integrates with Human DNA 
followed by disruption of the E1/E2 open reading frames and Up 
regulation of E6 and E7 proteins. This E6 and E7 proteins binds with p53 
pRB and tumor suppressor protein respectively. A key carcinogenic 
process is production of E7 protein by the virus which interferes with 
the host pRB    (retinoblastoma protein) tumor suppressor protein. The E6 
protein of the virus is capable of destroying the p53 protein of the host 
cell, which inhibits accumulation of genetic mutation during replication 
usually through apoptosis, resulting in proliferation occurs in viral 
infected cells. 
22 
 
             The development of genital and anal carcinomas from the 
persisting anogenital warts are considered to be rare. More often, these 
cases involve verrucous carcinomas, which are HPV 6 and 11 positive. 
Cervical carcinoma, as well as penile and vulvar carcinomas are 
considered to have originated on the basis of premalignant neoplastic 
lesions, known as CIN (cervical intraepithelial neoplasia), AIN (anal 
intraepithelial neoplasia), VIN (vulvar intraepithelial neoplasia), and 
PIN (penile intraepithelial neoplasia). By definition, bowenoid papulosis 
represents a severe form of penile, perianal  and vulvar neoplasia. 
About one-fourth of women with anogenital warts present with 
similar vaginal and/or cervical alterations, and this makes colposcopy 
inevitable.  Bearing in mind that cervical carcinoma is considered and 
recorded as a sexually transmitted disease, according to the World 
Health Organization, the determination of cervical or vaginal intra-
epithelial neoplasia and the application of the respective therapeutic 
concepts according to the location and dimensions of the lesions is of 
paramount importance for the patient's prognosis. 
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HPV IN IMMUNOCOMPROMISED 
Immunocompromised state alters the natural course of HPV 
infection. Increased incidence of genital wart and persistence of HPV 
infection is seen in immune compromised individuals with decreased 
cell mediated immunity such as leukemia, lymphoma and AIDS. 
Prevalence of HPV infection and Ano genital wart is higher in Organ 
transplanted individuals24. The prevalence of cervical and anal 
Squamous intra epithelial lesion(SIL) is higher in women with renal 
transplantation17. HPV16 and HPV 18 DNA were found more often in 
immunosuppressed individuals 17, 18. The prevalence of HPV infection 
was higher in HIV infected women whose CD4+ count was less than 
500 cells/mm3 (20). The prevalence of high risk HPV’s like HPV 16, 18 is 
high among HIV seropositive individuals. Multiple HPV types are also 
common in HIV infected individuals19. The persistence of the infection 
with high risk HPV types is found in persons with CD4 count 
<200cells/mm320. Most important factors for high grade SIL s have 
shown to be low CD4 count, persistent HPV infection, infection with 
multiple types of HPV and infection with oncogenic type of HPV21. The 
increased risk of malignant transformation is due to the TAT protein of 
HIV virus which potentiates the expression of E6 and E7 region of HPV 
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1622. Patients with HIV infection commonly develop Papilliferous 
lesions of oral cavity with predominant association of HPV type 7 and 
3223.   
 
CLINICAL FEATURES 
HPV after entry may remain dormant without producing any 
lesion25 or may produce symptomatic or asymptomatic lesions. The 
lesions can occur after the incubation period of 1 -8 months with an 
average of 3months. In uncircumcised men, the preputial cavity, glans 
penis, coronal sulcus, frenulum, inner aspect of the foreskin are most 
commonly affected, while in circumcised men the shaft of the penis is 
often involved.  Warts may also occur on the scrotum, groin, perineum, 
and anal area. Wart in urethral meatus is common in men (25%) but in 
women its incidence is only 4 to 8 %. In women common sites are 
posterior part of introitus, labia, perineum and perianal region. The 
lesions can also be seen intra vaginally or in the cervix. But these are 
affected more in sub clinical infections. 
Depending upon the clinical appearance, warts can be classified as  
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Condylomata Acuminate  
Acuminate warts are found in mucosal surfaces and are 
characterized by pedunculated mass red to pink or white in colour with 
warty digitations, irregular surface and fissures and are seen mostly in 
partly keratinized epithelium26. 
Papular wart 
            Non pedunculated hemispherical masses or dome shaped masses 
1 to 4mm in diameter located on fully keratinized epithelium26 and lack 
the finger-like surface irregularities of acuminate warts. 
Keratotic wart  
These are firm papular lesions of varying sizes with slightly rough 
horny surface with no pedicle, ranging from a few mm to a few cms 
seen on the dry areas like shaft of penis, outer aspect of prepuce, labia 
majora and perineum26. Sessile warts are tiny lesions with no horny 
surface seen on fully keratinized epithelium. 
Flat topped papular wart   
These appear macular to slightly raised lesion seen on the 
partially or fully keratinized epithelium26. 
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Bowenoid papulosis    
Variant of papular wart characterized by hyper pigmented dome 
shaped, smooth, velvety, flat topped papules of size 7 to 10 mm in 
diameter. The colour of the lesion on mucous membrane sites is 
brownish or salmon red or greyish white and on cutaneous sites ash grey 
to brownish black. Bowenoid Papulosis appears at 25–35 years. 
Histologically high grade squamous intra epithelial neoplasia and is 
positive for HPV 16 DNA. Recurrence rate is 20%.   
“GIANT CONDYLOMA” or Buschke Lowenstein tumour 
           This is a very rare variant of HPV 6 and 11 associated disease. In 
HIV infected patients Anogenital warts tend to be multiple and even 
diffuse. Usually asymptomatic sometimes they develop very large 
lesions and become locally invasive and destructive but non 
metastasizing tumors seen in shaft of penis, vulva and perianal areas26. 
In soft areas lesions have papillomatous surface whereas in hard areas 
the surface is smooth. There is a significant risk of transformation of this 
giant wart into squamous cell carcinoma.A complex histological pattern 
may exist with areas of benign condyloma intermixed with foci of 
atypical epithelial cells or well differentiated sqamous cell carcinoma. 
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Diagnosis of Buschke-Loewenstein tumour often requires multiple 
surgical biopsies, computed tomography or magnetic resonance 
imaging. 
Anal Warts  
Occurs commonly in homosexuals. It is also seen in children 
subjected to sexual abuse, immunocompromised persons and along with 
genital wart. 
Oral Warts  
As a result of oral sex are commonly seen over the lips, tongue 
and palate. 
HPV IN SPECIAL SITUATIONS 
PREGNANCY 
 Anogenital warts increase in number and size due to increased 
vascularity, hormonal influence and decreased cell mediated immunity 
is seen. It usually resolves after delivery but sometimes excessive 
bleeding may occur or it may remain as such52. Complications like 
dystocia, fetal laryngeal papilloma, bleeding and ulceration are not 
uncommon.   
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WARTS IN CHILDREN  
Mode of infection is uncertain.   If acquired during delivery results in 
genital and laryngeal disease. It can also occur as a result of sexual 
abuse or rarely through non sexual contact within the family. 
DIFFRENTIAL DIAGNOSIS 
ANATOMICAL 
Skin tag, Pearly Penile Papule, Ectopic sebaceous glands, Dry 
smegma, Anal tag and Mucosal tag. 
PATHOLOGICAL 
Condyloma lata, tuberculosis verrucosa cutis, Venereal 
granuloma, Lympho granuloma venereum, Squamous cell carcinoma, 
Seborrhoeic keratosis, Molluscum contagiosum, Lichen planus, 
Hirsutoid papillosis, Lipoma, Herpes, Urethral caruncle, 
Schwannoma27, Granuloma, Sentinel piles and Focal dermal 
hypoplasia28(Goltz syndrome). 
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VERRUCOUS LESION 
Tuberculosis verrucosa cutis, Verrucous type of granuloma 
inguinale, Malignancy, Condyloma lata of syphilis, Non- venereal 
treponematoses, Skin tag. 
PAPULAR WARTS 
Pearly penile papules, Herpes progenitalis, Molluscum 
contagiosum, Fordyce's spots, Urethral caruncle and Foreign body 
granuloma. 
DIAGNOSIS  
             Most of the cases are diagnosed clinically. Rarely it requires 
biopsy and histopathological examination to make the diagnosis. The 
acetic acid test may be valuable for delineation of disease before biopsy 
and surgical treatment. 
HISTOPATHOLOGICAL EXAMINATION31 
  The histological characteristics of the classical protuberant type of 
condyloma acuminatum in the anogenital region are mainly varying 
degrees of parakeratotic hyperkeratosis, moderate granulomatosis, 
pronounced acanthosis, marked papillomatosis and thickening and 
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elongation of rete ridges. A branching fibro vascular core is seen in the 
dermis. Other clinical variants have similar features but less pronounced 
fibro vascular branching. The most characteristic feature for the 
diagnosis is the presence of epithelial cells with distinct perinuclear 
vacuolization, such cells are known as koilocytes(Greek ward koilos 
means empty).The vacuoles in koilocytes are sharply demarcated from 
the peripheral rim of cytoplasm. The nucleus is large hyper chromatic 
and pushed to periphery of the cells. Intra nuclear basophilic inclusions 
are also seen.  It is important to remember that vacuolization is normal 
feature in the upper portion of mucosa, therefore, it is considered 
pathognomonic only if it extends to the deeper layers of stratum 
malpighii. Hyperkeratosis is not a feature of condyloma acuminatum of 
the genital area where the stratum corneum consists of one or two layer 
of parakeratosis. In genital wart virus particles are scanty 
ACETIC ACID TEST30 
      Following application of 5% acetic acid, HPV lesions may turn 
greyish white within few minutes. As the test has poor specificity it is 
only recommended for use in specialist settings where colposcopy is 
available and is not recommended for screening purposes. However, it 
may be valuable in identifying lesions for targeted biopsy and for 
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demarcating lesions during surgical therapy. False positive results are 
commonly due to inflammatory conditions (For example, lichen 
sclerosus et atrophicus, lichen planus, psoriasis, balanoposthitis and  
Vulvovaginitis, eczema, genital herpes, and traumatic micro abrasions) 
and give rise to ragged, irregular acetowhite borders. There may be 
varying degrees of underlying hyperaemia and capillaries lack the 
vascular punctuation suggestive of HPV.  
IN CASE OF CERVICAL AND VAGINAL WART 
Speculum examination, Colposcopic examination and Pap smear fixed 
in ethanol and stained with papanicolou stains are useful to diagnose 
squamous intraepithelial neoplasia. In doubtful cases, acetowhite 
staining to be done with 3 to 5 % acetic acid. 
 Cytological diagnosis of SIL 
     Cytological diagnosis is based on Bethesda system. Terms used in 
this systems are Low grade squamous intra epithelial lesion (L-SIL) and 
high grade squamous intra epithelial lesion(H-SIL).  
L-SILs previously classified as mild dysplasia(CIN 1) denotes 
protective HPV infection with variety of HPV types. The cell nuclei are 
enlarged often angulated, hyper chromatic and multinucleated cells may 
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be seen. Cells with vacuolated cytoplasm (koilocytes) are found in the 
superficial layer of cervical epithelium. The cells contain diploid or 
polypoid DNA pattern. 
H-SILs, previously classified as moderate - severe dysplasia, 
composts of proliferating basal type cells that have a high nuclear to 
cytoplasm ratio. The lesions are usually aneuploid.  
   Ultra structural studies show virus in some of the cell nuclei as 
particles. These particles are crystalloid aggregates and can be diffusely 
located in chains and/or groups. Routine application of electron 
microscopy in the initial diagnosis is not considered as a standard 
method now. Viral antigen can be demonstrated in the nuclei of cells in 
the stratum granulosum by peroxidase- anti peroxidase test, indirect 
immunoflourescence and indirect immune alkaline phosphatase 
reaction.  
 The most sensitive method of detection of HPV infection is 
HPV DNA PCR which is primarily used for research purposes only. 
PCR performed with the help of specific PCR group-specific probes is a 
highly sensitive and promising method finding wider application in 
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modern dermatology clinics. This method helps to prove the presence of 
even the smallest quantities of papilloma viruses in the cells. 
      DNA hybridization of histological tissues by means of both 
radioactive and non-radioactive techniques can be performed on HPV-
infected cells. Due to the fact that this technique is not suitable for the 
detection of high-risk malignant HPV strains and is also time and labor 
intensive; with sensitivity which is similar to PCR methods, its 
application is limited. 
  Gel electrophoresis and restriction endonuclease cleavage32, 
Southern blot hybridization, Filter in situ hybridization, Dot blot 
hybridization are other methods employed in detection of viral warts. 
Anal warts may require proctoscopy for diagnosis and 
Urethroscopy or meatoscopy for diagnosis of urethral warts. As a rule, 
posterior urethra is not involved without previous or simultaneous 
growth of meatal warts. 
MANAGEMENT OF ANO-GENITAL WARTS 
Although most Anogenital warts in immunocompetent patients 
eventually undergoes spontaneous regression, treatment is offered to the 
majority of affected individuals with moist hyperplastic condylomata 
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acuminata to reduce the risk of secondary infection and to alleviate 
anxiety. Soon after the diagnosis of the Anogenital wart all patient 
should be counseled carefully about the infection. Before initiation of 
wart therapy it is important to attend local infection whether it is 
sexually transmitted or not. All treatments of HPV infections have 
significant failure and relapse rate. A number of treatment modalities is 
available for Anogenital wart and are listed below, broadly divided into 
medical and surgical modalities as follows. The efficacy of the various 
treatments available for use in treatment of external anogenital warts has 
recently been reviewed by Beutner and Wiley33.  
Patient counselling—key points 29 
• Patients should receive clear information, preferably written, as to 
the cause, treatment, outcomes, and possible complications of 
anogenital warts 
• Reassure patients that although wart clearance may take 1–6 
months and recurrences may occur, complete clearance will occur 
sooner or later 
• Smokers with recalcitrant lesions should stop smoking as a 
correlation exists with wart development. 
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• Advise female patients about regular participation in cervical 
cytology screening programmes. Reassure that risk of cervical 
cancer is low and ample time exists for detection and removal of 
any CIN. 
Treatment—key points29 
• First line treatment will achieve clearance in most patients within 
1–6 months, although disease persists in up to one third of 
patients 
• Home therapy can be proposed in most cases as first line therapy 
for first attack of acuminate warts. Acuminate warts respond in up 
to 90% but papular and macular lesions in only 50% of cases. 
•  Few, small lesions can be easily treated under local anaesthesia 
by scissors excision, diathermy, cryotherapy  or TCA. 
•  TCA should not be used on large lesions and multiple sessions 
are not well tolerated by patients. 
•  Lesions occurring at new sites during treatment or after clearance 
do not necessitate a change of the treatment modality. 
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•  Persistence or reappearance of the treated lesion is usually an 
indication to switch to another treatment modality. 
•  Patients should be evaluated regularly until the warts are cleared. 
•  Patients should be informed that periods of coital rest throughout 
the course of the therapy might reduce therapy related symptoms 
such as pain or discomfort. 
MEDICAL THERAPY 
         20%Podophyllin, 0.5%Podophyllo toxin (0.5%),5% w/v 5 
flurouracil,80-90%Trichloroaceticacid,Bicloro ethanoic acid, Interferon, 
5%Imiquimod, Inosine pranobex, Cidofovir.  
Immunotherapy – Intralesional mycobacterium w vaccine 
SURGICAL THERAPY 
Scissor excision,Electro surgical methods like Electro cautery,Electro 
fulguration, Electro desiccation, Cutting 
CRYOTHERAPY  
LASER THERAPY 
PHOTODYNAMIC THERAMEDICAL THERAPY 
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PODOPHYLLIN 
           Kaplan first described the use of podophyllotoxin in 1942. It is 
ethanol extract prepared from the dried rhizome and roots of plant 
podophyllum species (podo – foot, phyllum-leaf) American species 
podopyllum peltatum grows in moist shady places from New England to 
Caroline. A second species of therapeutic interest is podophyllum 
emodi. It is seen in Himalayan mountains and Kashmir. 
Preparation of podophyllin 
 Syrupy ethanal extract is poured into cold water and then 
acidified with hydrochloric acid to form a precipitate which is dried and 
powdered, Light brown to greenish yellow in colour, it darkens on 
exposure to light and heat. In podophyllum peltatum the lignan content 
was found to consists of podophyllotoxin 10% and alpha and beta 
peltatin 13%. In extracts from P.emodi ,  Podophyllotoxin was 40 % and 
4 – d methyl podophyllotoxin 2%. Unfortunately the amount of active 
material in any extract varies considerably from batch to batch34, as does 
the amount of lignans such as quercetin which are responsible for most 
of the side effect of the drug. The suspension has a relatively short half 
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life, although probably stable up to 3 months without undue loss of 
potency. 
Mode of action 
Podophyllotoxin has been shown to be the most active lignan 
contained in podophyllin resin35, 36 and produces destructive effect on 
keratinocytes and dermal cells, at low concentration (1 mmol).  
Podophyllotoxin acts in a similar manner to colchicines and binds to site 
of tubulin, a component of microtubules. Microtubules form the 
principle fibrous protein of the mitotic spindle and are an essential 
component of the biological machinery that moves chromosome and 
other cytoplasmic components. It arrests cell division in metaphase 
stage. At higher concentration (10 to 100 mmol) podophyllotoxin 
inhibits nucleoside transport and leads to cell destruction37.  
Recommendation for podophyllin use 
              25% Podophyllin in tincture benzoin once or twice a week,  the 
suspension being washed off after 4 to 6 hours. Available as   various 
formulations38,  the  drug can be given about 0.5 ml  once only as 
application by trained personnel with adjacent skin being protected by 
yellow or white soft paraffin. The use of single container for repeated 
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applications in clinics is condemned as it may bring risk of cross 
infection. It is good practice to treat with small amounts of 25% 
podophyllin in liquid paraffin or methylated spirit of not more than 
0.3ml at a time at frequent interval of every 3 to 7 days. Patient should 
be advised to wash off podophyllin after an interval of 4 to 6 hours. The 
application of podophyllin to large condylomata (more than or equal to 
10 cm square area) often results in extensive tissue necrosis with pain 
and swelling and caution should be taken in using podophyllin in 
treatment of such lesions. 
Clinical effect 
About 4 to 6 hours following application of podophyllin the 
treated condylomata show blanching and later a drying effect is seen 
when the pink or red moist wart appear white or grey and dry, 
sometimes there is dark brown discoloration. In 4 to 24 hours the 
condylomata decrease in size and in 48 hours there is complete 
involution39. The penetration of podophyllin was prevented by the dry 
keratinized surface which caused treatment failure in some cases. 
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Unwanted effects 
Varies from  local itching, burning, tenderness , erythema , pain, 
swelling and ulceration. Balanoposthitis may be severe with or without 
phimosis, if neglected lead to a necrotizing balanitis. When podophyllin 
has been used aggressively and in quantities beyond that is 
recommended, systemic ill effects have been recorded including 
dizziness, lethargy, pre coma, nausea, vomiting, abdominal pain, 
respiratory distress and cold clammy skin. Reversible bone marrow 
suppression with thrombocytopenia and leucopenia has been 
recognized40 and irreversible peripheral neuropathy may occur followed 
by systemic toxicity41. In pregnancy, the drug is potentially mutogenic 
and it causes teratogenecity theoretically41. 
Efficacy 
At least 3 months after the cessation of the therapy, the reported 
clearance rate of anogenital warts was between 22% to 73%.  The 
recurrence rate was between 23% to 55%33.  
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PODOPHYLLOTOXIN 
Active agent of podophyllin has been purified and available as 
liquid and cream. It is considerably more expensive than podophyllin 
but is suitable for home treatment.   
Preparation 
Available as acidic solution in ethanol 0.5%w/v and as a cream or 
gel 0.15%w/v        
Recommendation for podophyllotoxin use 
Podophyllotoxin (0.5% w/v) is applied twice daily for 3 days of 
each week for a maximum of 4 weeks.volume of the solution should not 
exceed 0.5 ml or 50 single application per session and the area treated 
per session with solution, cream or gel should not exceed 10 cm 
square.it is recommended that physician or nurse should apply the first 
treatment to demonstrate the proper application43 . 
Unwanted side effects 
Mild tenderness, burning and pain are common; erythema , edema 
and minor erosions are also frequently seen33. The highest incidence of 
these effects is seen during the first week of treatment42.  
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The safety of podophyllotoxin in pregnancy remains to be 
established and is probably best avoided as of now. 
Mode of action and clinical effects are similar to podophyllin. 
Efficacy 
Compared with podophyllin, podophyllotoxin is more effective in 
producing complete clearance of warts after 6 weeks of treatment. 
Complete clearance after 6 weeks of therapy podophyllotoxin was 88% 
whereas with podophyllin clearance rate was 63%.61     
MONOCHLOROACETIC ACID & TRICHLOROACETIC ACID 
The use of caustic agents such as mono or trichloroacetic acid is 
of value especially in the treatment of keratinized wart. The acid acts by 
coagulating tissue protein with resultant necrosis. The acid in an 80% to 
90% w/v solution in water is applied once weekly to the wart. The agent 
is best applied by touching the wart with an orange stick that has been 
dipped in the acid. It should not be applied with a swab as the amount of 
acid may be excessive and may damage adjacent normal skin. Care 
should be taken to avoid contact with adjacent normal skin.  Patient 
often experience a warm sensation on application of the acid and the 
solution should be allowed to dry before the patients sit or stand43. The 
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treated area rapidly goes white. The use of such agents at the meatus is 
best avoided as scarring leads to meatal stenosis.  Local ulceration and 
pain may occur44. If the pain is intense it can be neutralized by dusting 
with sodium bicarbonate. There is no systemic toxicity and thus is safe 
to use in pregnancy. 
Efficacy 
In patients with  Anogenital wart, treated with 95% TCA solution 
and cryotherapy for the period of 6 weeks.70% of TCA patients and 
86% of cryotherapy patients shows complete clearance of the wart 
3month after completion of treatment. But local ulceration was noted in 
patients treated with TCA44.   
CRYOTHERAPY 
Liquid nitrogen, carbon di oxide or nitrous oxide can be used as 
cryogens. It can be used on keratinized and unkeratinized warts; it is not 
restricted to use at specific anatomical sites and is safe in pregnancy. 
The perianal wart does not respond as well as genital warts to freezing. 
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MODE OF ACTION45 
  Cryotherapy destroys warts by cytolysis directly as a result of 
formation of intracellular ice crystals and later thawing; and from a 
injury to microcirculation as a result of vasoconstriction and damage to 
endothelium which causes thrombosis in arterioles and venules of the 
tissues. The optimum temperature required to induce cell death is 
around  -50 degree Celsius or lower. The effectiveness of cryotherapy 
can be assessed by its formation of an iceball of 1 to 2 mm beyond the 
periphery of the lesion45. Within 30 seconds of freezing, cells begin to 
show pyknotic nuclei edema and other cytoplasmic changes. At the edge 
of the frozen area, cells have eosinophilic cytoplasm and basophilic 
nuclei. Cellular infiltrate is mainly polymorphonuclear cells with some 
lymphocytes and plasma cells most obvious at the edge of the frozen 
area. Destruction of epidermal cell is associated with vesiculation 
followed by sloughing. Resolution begins within 3 days and healing 
usually occurs without scarring 46.  
Cryotherapy  methods 
          The application of liquid nitrogen of boiling point of -195.8 
degree Celsius to discreet warts is often used. The aim should be to 
45 
 
freeze the wart until a halo of frozen skin is just visible at the base. A 
cotton wool dipped applicator can be immersed in a vacuum flask of 
liquid nitrogen and then applied to the wart exposed and immobilized by 
stretching the skin between the fingers.  
          A hand held insulated and pressurized flask filled with liquid 
nitrogen and with a control valve to which a range of sprays of different 
diameter may be fitted is satisfactory for the treatment of most external 
genital warts. The risk of cross infection is minimal by using this 
method.  
         Closed cryotherapy system operate by providing a continuous 
supply of liquid nitrous oxide or carbon dioxide from a cylinder to a gun 
that controls the flow of liquid gas to a removable probe. To prevent 
cross infection, probes must be autoclaved before use on to different 
patients. 
Efficacy 
3 months after the clearance of external genital wart with 
cryotherapy is 63% to 93%33 .Perianal wart do not respond to 
cryotherapy as good as genital wart62.          
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Side effects 
About 20% of the patients have mild pain during and for a few 
hours after the treatment. More severe pain and ulceration with 
secondary infection has been reported in the treatment of perianal wart 
with liquid nitrogen compared to genital wart47. 
IMIQUIMOD 
         It is an immune response modifier that has a potent anti tumor and 
antiviral activity. As it modulates innate immunity by activating 
macrophages thereby inducing type 1 response considered responsible 
for wart regression. More expensive compared to other forms of 
treatment. Not suitable for the treatment of long standing and fibrotic 
wart.  
Mode of action48 
Local application of IMIQUIMOD releases  cytokines including 
interferon gamma, tumor necrosis factor alpha, IL-1 alpha, IL-1 beta, 
IL-6, IL-8 , IL-10, IL-12, GM-CSF, G-CSF, MIP-1 alpha, IL-1 receptor 
antagonist by peripheral mononuclear blood cells and lymphocytes. 
IMIQUIMOD induces cytokine expression in keratinocytes resulting in 
TH-1 response. There is no direct anti viral activity. 
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Recommendations of IMIQUIMOD use 
5% cream is applied to wart with finger, 3 times per week every 
other night up to 16 weeks. The area is washed with mild soap and water 
6 to 10 hours after application. The most commonly reported side effect 
is local irritation. As the cream may weaken condom and diaphragm 
alternative means of contraception should be considered until treatment 
has been completed. 
Efficacy 
No significant difference between vehicle and imiquimod with 
respect of complete clearance of the wart in immune compromised 
patients. But with imiquimod, reduction in wart area of >50% is 
reported.63 but in immune competent patients,37% of 51 showed 
complete resolution of wart  with in 8 weeks of treatment period65. 
Side effects 
Erythema and local irritation develops in majority of individuals 
treated  with IMIQUIMOD but excoriation and erosions are found in 
less  than 50% of the  patients. Indurations, vesiculation, scabbing, 
ulceration occur less commonly. The safety of IMIQUIMOD in the 
treatment of genital wart in pregnancy has not yet been established. 
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Other Immunomodulatory agent is inosine pranobex whose efficacy has 
not yet been proved49.  
5 FLOUROURACIL 
This antimetabolite has in the past been used topically for the 
treatment of wart. It is a pyramidine analogue that is incorporated into 
RNA in preference to natural substrate of uracil. It inhibits thymidalate 
synthetase thereby impairing RNA and DNA synthesis. It becomes 
effective in S phase of cell cycle and causes disturbance of cell growth 
and division. Available as 5% cream, the cream is applied once or twice 
per day to the wart until they regress or until pain or ulceration 
necessitates cessation of treatment. It can also be used for 2 consecutive 
nights per week for 10 weeks. Condylomata at the urethral meatus 
responds well to 5FU cream applied daily for 3 weeks 
Side effects - irritation and ulceration limits its use. 
INTERFERONS 
Interferons are endogenous intracellular proteins possessing not 
only antitumor but also antiviral and immunomodulating effect.  The 
application of interferon α is already a standard therapy in a number of 
countries in Europe and the USA. Several studies have shown good 
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results of systematic therapy with interferon in combination with a CO2 
laser, surgical methods and electrodessication. The subcutaneous 
application of interferon α2a and interferon α2b within three cycles of 
one week each, at doses of 1-3 MIO I.U. is recommended as a good 
preoperative option.  The intermission between each cycle lasts 
approximately 4 weeks. Its advantage compared to an intralesional 
application is the absence of pain and frequent visits to physicians.  It is 
very interesting that Interferon does not always have a synergistic effect 
with other treatment modalities in the treatment of condyloma. 
Subcutaneous IFN α2a combined with cryotherapy was no more 
effective than cryotherapy alone in the treatment of primary anogential 
warts.  Similarly, IFNα2a in combination with podophyllin was no more 
effective in the treatment of primary anogenital warts than podophyllin 
alone and is associated with more adverse events.  
However combining Interferon with other treatments increases the 
likelihood of effective treatment. The additional application of 
subcutaneously administered interferon α2b to laser treated patients with 
resistant genital lesions significantly enhanced the chance of eliminating 
these warts.  There are also data that suggest a gel containing interferon 
helps to treat vaginal warts.  
50 
 
There are drawbacks due to the side effects of interferons, which 
are most frequently in form of sub-febrile temperatures, headache and 
faintness. Interferon α in the form of a gel shows good compatibility.The 
application of this gel containing 0.15 Mio I.U/g interferon-α, to patients 
whose warts have been surgically removed was compared to the 
application of a placebo gel after one-month of use. The subsequent 24-
month observation showed that 75% of the patients treated by the 
placebo gel had recurrences. Fifty-four percent of the patients treated by 
interferon gel also showed recurrences. The high percentage of the 
patients who have profited from the local application during the 
postoperative period is the basis for the more and more frequent 
application of this preparation. It is suggested that interferon is able to 
protect the basal keratinocytes from HPV infection by  the activation of 
Th-1 cells and their cytotoxic effect is probably the basis of the effect.  
The combined systemic therapy of anogenital warts by interferon 
α2a and isotretinoin (0.5-1 mg/kg/d) has promising effects.  Promising 
also are current results of single use PEG-IFN (pegylated interferon- α) 
80 microgram per week for 24 weeks, which led to full remission in 
HIV-positive patients at the stage of viraemia. Interferon α has probably 
an additional suppressive impact on viral replication with a synergetic 
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effect added to the effect mediated by T Lymphocytes. They are 
expensive and side effects like flu like symptoms are common.  
CIDOFOVIR 
Cidofovir is an acyclic nucleoside phosphonate with a wide-range 
antiviral effect with respect to some HPV-induced tumors. This 
substance can be locally applied in the form of 1% or 3.5% gel or 
ointment, as well as administered intravenously.  The substance can 
provoke programmed cell death among the cells of the tumor 
population. This preparation also gave good results when applied to the 
inguinal area of a 3-year old patient. The topical single perianal use of 
1% cidofovir in the form of an ointment in HIV-positive patients led to 
full remission within 14 days and absence of any recurrences of warts 
during the next 14 months.  Cidofovir provides good results as adjuvant 
therapy after electrodessication and operative removal of CIN, PIN and 
VIN.  
ELECTROCAUTERY 
              The thermal damage to wart tissue results from the application 
of a resistant wire heated with an electric current. It is an effective 
treatment in case of genital warts that are discreet and pedunculated. The 
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aim should be to coagulate the wart down to the basement membrane 
and cause minimal damage to surrounding skin. Before the procedure 
topical 1% solution of lidocaine is used as a local anaesthetic. The 
ulceration during the electrocautery is inevitable but usually heals within 
7 to 10 days with little scarring. 
ELECTROSURGICAL METHODS 
           In this method heat is produced in the tissue at the point of entry 
of high frequency current50. Several methods which may be useful in the 
treatment of genital warts are 
Electro fulguration 
 High voltage low amperage current sparks across an air gap 
between the electrode and the wart without touching it. There is little 
thermal damage so healing is rapid. 
Electrodessication 
Similar to electrofulguration except that the electrode is in direct  
contact with the tissues. 
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Electrocutting 
Electrocutting Occurs under the conditions of very high current 
density when temperature rises rapidly and sufficiently to damage the 
tissues51. Cutting diathermy is generally used in the treatment of large 
condylomata and its use may require general anesthesia. Large loop 
excision of T zone of the uterine cervix is used in suspected SIL and 
cervical condylomata.  Local anesthesia for this procedure is necessary 
(Prilocaine hydrochloride 30 mg/ml into the cervix with a dental 
syringe). 
Efficacy 
10 of 11 patients treated with ECT shows complete clearance of 
the wart 3 months after treatment by Simmons et al64. 
Unwanted effects 
Intensive coagulation can result in slow wound healing, secondary 
hemorrhage, infection and scarring 50.It can also lead to complications 
like burns, electrocution, fire and interference with cardiac pace maker.  
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SCISSOR EXCISION 
Scissor excision of perianal and intra anal wart can be done under 
general anaesthesia with wart bearing area being infiltrated with saline 
adrenaline solution. The wart that has separated and become discrete are 
then removed with fine pointed curved scissor by cutting at the base of 
the wart from back to front. Cell mediated responses were measured and 
this appears to be enhanced by this technique. The recurrence rate 
following scissor excision is low when compared to patient treated with 
podophyllin. 
IMMUNE THERAPY 
Intralesional mycobacterium w vaccine: Patients with anogenital 
warts to be injected with mycobacterium w vaccine 0.1ml initially in the 
deltoid region on both sides. Two weeks later, mycobacterium w 
vaccine to be injected Intralesionally into few lesions of genital warts. 
Then Intralesional injections to be repeated every week till the complete 
clearance of the lesion occurs or for a maximum of 10 weeks.  
LASER THERAPY 
CO2 laser is most widely used in the treatment of anogenital wart. 
Infrared radiation produced by the laser is focused by series of mirrors 
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and lenses. All types of tissues absorb this energy; different power 
densities produce different biological effects. A beam of 0.1 mm 
diameter is suitable for incising tissues whereas a defocused beam of 
about 2mm spot size can be used to vaporize the tissue. Around the zone 
of vaporization there is a margin of coagulation51. As thermal necrosis 
of healthy tissue is limited to about 50 micrometer beneath the zone of 
vaporization. Smoke evacuator is necessary for vaporization. 
Laser therapy is seldom used as a first line treatment for 
Anogenital wart. As there is a perfect control of tissue destruction and a 
reduced risk of hemorrhage this form of treatment may be preferable to 
electrocautery, diathermy or scissor excision in the management of 
extensive lesions.  Flash lamp pulsed dye laser can also be used without 
much side effect. Good results in removing HPV-associated lesions are 
achieved by ERB YAG laser. 
Disadvantage 
However, laser treatment is more complex and costly than 
electrosurgery or cryotherapy. It needs additional training to operate the 
laser equipments. Larger lesions and some patients (especially children) 
may require general anesthesia.As HPV DNA may be released during 
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laser vaporization of genital HPV infected lesions; there is more chance 
to infect the operator. Risk factors for transmission of genital warts by 
vaporization are the HPV type, thickness of the skin and viral burden.  
The risk of scarring is greater than in cryotherapy. 
Clinical efficacy 
The efficacy of laser treatment ranged from 23% to 52% with 3-
18 months follow up. Recurrence rates ranged from 60% to 77%. On 
comparing extensive genital warts in HIV-positive and HIV-negative 
patients, the clearance and recurrence rates were similar for both groups. 
In some rare cases of inter-anal warts located closely to the linea 
dentata, some invasive methods have been described such as loop 
colostomy. The purpose of these techniques is to minimize the 
contamination over the linea dentate. 
VACCINATION 
Papilloma viruses are difficult to reproduce under in vitro 
conditions, so generation of a "normal” vaccine is impossible. Vaccine 
can be prophylactic or therapeutic. Vaccine preparation based on 
generation of virus-like particles (VLP), which are recombinant version 
of major capsid protein of relevant HPV types.  Antibodies formed 
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against VLP are neutralizing antibodies which are seen in sufficient titre 
in genital secretion which can protect from HPV infection53. The VLP 
lack nucleic acid and are thus incapable of replication and are non 
infectious. 
Bivalent vaccines contain, virus like particles of HPV 16 and 18 
types. Bivalent vaccine offer protection against cervical intraepithelial 
neoplasia. The tetravalent vaccine contains virus like particles of 16,18,6 
and 11 types and therefore, it additionally protects against condylomata 
accuminata.  
The bivalent vaccine contains, in the form of adjuvant not only 
aluminium salts but also ASO4 (monophosphoryl lipid A). This 
ingredient is purposed to intensify the immune response. ASO4 is able 
to induce higher antibody titer levels on one side and on the other side 
have longer persistence in patient’s serum in contrast to a similar 
vaccine containing aluminum salts only.  
The recommendations concerning  vaccination of bi and 
tetravalent vaccines are approximately similar. Regarding the bivalent 
vaccine, triple intramuscular application of 0 and 1 and 2 months is 
recommended, and regarding the tetravalent vaccine 0, 2 and 6th month 
application is recommended. The single vaccination dose contains 0.5 
ml or 20-40 μg of antigen of the respective virus-like particles. 
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The tetravalent vaccination against HPV 6, 11, 16 and 18 (Gardasil™) is 
the most popular one.  
Therapeutic vaccine 
Although neutralizing antibodies produced against VLP can 
prevent the disease but cannot alter the course of the disease, for which 
it needs cell mediated immune response.  
Other therapeutic vaccines for the treatment of genital warts are 
fusion protein vaccines54, but its clinical efficacy is less. The concept of 
so called chimeric vaccines, that is VLP with addition of an early 
protein55 theoretically has both therapeutic and prophylactic function. 
PARTNER MANAGEMENT 
Current partners and if advisable, other partners within the past 6 
months should be assessed for the presence of lesions and for education 
and counselling about STDs and their prevention.  
PREVENTION 
Regular use of condom can reduce the risk of acquiring genital 
warts56.The use of condom not only during treatment, but three months 
after post treatment can prevent transmission as well as recurrence. 
However there is no scientific justification regarding this statement. 
59 
 
PROBLEMATIC GROUPS OF PATIENTS AND SUPPLEMENTARY 
THERAPEUTIC ALTERNATIVES 
The fact that podophyllotoxin, interferon α, and imiquimod are 
contraindicated during pregnancy must be considered. Their side effects 
such as intrauterine death and the appearance of different malformations 
(podophyllotoxin) are the basis of this contraindication.  The application 
of highly concentrated (85%) trichloracetic acid is a good therapeutic 
alternative during pregnancy.  In case of strong pains and concerns of 
overdosing, rapid neutralization is possible with sodium bicarbonate.  
The second problematic groups are children infected during birth 
by HPV 6, 11 and in rare occasions by HPV 16, 18, 31 and 35 viral 
strains. Cryosurgery, electrodessication and laser ablation under a short 
incubation narcosis are suitable options for this group of patients.  
Therapy of patients suffering from AIDS and transplant recipients 
is frequently difficult but rarely ineffective. The reason is in the 
multifocal invasion of the lesions due to the weakened T-cell immunity. 
Because of this weakness, recurrences frequently arise. Surgical removal 
followed by prophylaxis with cidofovir/interferon gel provides 
promising results. 
60 
 
AIM OF STUDY 
To study the prevalence of HPV infection in HIV infected and 
NON HIV infected individuals and to analyse the different treatment 
modalities.  
OBJECTIVES        
• To study the prevalence of HIV infection among STD male OPD 
attendees  
• To study the prevalence of genital wart among STD male OPD 
attendees 
• To study the prevalence of genital wart among HIV Non infected 
individuals attending STD male OPD. 
• To study the prevalence of genital wart among HIV infected 
individuals   attending STD male OPD. 
• To analyse the different treatment modalities and responses on 
exophytic anogenital wart those attending STD male OPD. 
• To compare the different treatment modalities and responses on 
exophytic anogenital wart among HIV Non infected individuals 
and HIV infected individuals those attending STD male OPD 
• To find out the difficulties in managing the patients with genital 
wart. 
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MATERIALS AND METHODS 
 A screening of HPV infection among male patients who attended 
Institute of Venerology, Government General Hospital, Chennai, during 
the period between June 2007 - May 2009, was conducted by means of 
history taking and clinical examination to find out Anogenital wart and 
HIV screening by ELISA method was done in this study after giving the 
pretest counselling.  CD 4+ count was done in the patients with HIV and 
genital wart.  Blood VDRL and routine laboratory investigations were 
also done.                               
Among the screened population a total of 98 male Anogenital 
wart patients were enrolled in randomized open clinical trial to analyse 
the different modalities of treatment response on exophytic Anogenital 
wart. Random selection was based on the day treatment  was started, i.e  
on Mondays 20% podophyllin with tincture benzoin solution, on 
Tuesdays 80% w/v trichloroacetic acid, on Wednesdays 5% imiquimod 
cream, on Thursdays  liquid nitrogen and on Saturdays electrocautery 
therapy.  
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Patients treated on Mondays were taken as study group I, 
similarly on Tuesdays, Wednesdays, Thursdays and Saturdays were 
taken as study group III, IV, II and V respectively.  
After getting informed consent, pre treatment counselling 
regarding the nature of the disease, its transmission, spontaneous 
regression and recurrence was given to those patients included in the 
study. Examination and treatment was given in examination couch in 
lying position. 
MATERIALS  
THE FOLLOWING TREATMENT MODALITIES WERE APPLIED FOR 
ANALYTICAL STUDY ON EXOPHYTIC ANOGENITAL WART 
Five types of treatment modalities were taken for this study. They 
were 20% podophyllin in 10% tincture benzoin solution, liquid nitrogen, 
80% w/v trichloroacetic acid solution, 5%imiquimod cream and 
electrocautery. Each therapy was given a maximum of 6 sittings except 
5% imiquimod cream which was given a maximum of 10 sittings. 
Interval between each sitting was 1 week except liquid nitrogen which 
was given at an interval of 2 weeks. 
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Patients were instructed to attend the STD OPD whenever he 
developed local or systemic discomfort. Here the common local side 
effects like itching, burning, erythema, pain, tenderness and erosion was 
considered as local acceptable (LA) side effects. Those who developed 
side effects like swelling, ulcer, necrotising balanoposthitis and 
phimosis were considered as local but not acceptable (LNA) side 
effects. 
Patient’s clinical responses were calculated as follows 
GRADE A - Lesions completely resolved. 
GRADE B - Lesions reduced in size but not completely resolved. 
GRADE C - Lesions not responding to treatment even after completion 
of treatment. 
DCT         - Treatment discontinued. 
Patients with GRADE A responses were considered as treatment 
success .If lesions did not respond to treatment or partially resolve even 
after 6 sittings (except 5% imiquimod) or patients who developed any 
local but not acceptable side effects or systemic side effects, their 
therapeutic modality was changed (TC). Patients who had partially 
resolved or not responding to treatment even after the completion of 
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their treatment after maximum period was considered as treatment 
failed. Patients whose treatment were changed during the course of 
treatment period for any reason (for example patient those who 
developed local but not acceptable level of side effects) are also 
considered as treatment failed. Patients who developed local but not 
acceptable side effects, their treatment were changed after curing their 
ill effects. Patients who were not coming for treatment during the course 
was considered as treatment discontinued (DCT). Anytime after the 
clearance of wart, Patients those who developed the lesion over the 
already resolved site were taken as recurrences. Treatment was changed 
for recurrent lesions. Patient was instructed to come to STD OPD 
whenever he developed new or recurrent lesions, others were instructed 
to attend STD OPD for follow up for after 3 months. Those who were 
not coming for follow up were considered as follow up failed.  
 1.   20% podophyllin in 10% tincture benzoin solution: After 
obtaining investigation reports, on every Monday, 0.3 ml of 20% 
podophyllin in 10% tincture benzoin was applied with cotton tipped 
swab once a week for a maximum of 6 weeks and the surrounding skin 
was covered with zinc oxide cream. Patients were instructed to wash the 
genitalia after 4 hrs. If there was no problem, the patients were 
65 
 
instructed to be reviewed on every Mondays for 7 weeks from the 
starting date of  treatment and patients were instructed to attend the STD 
OPD whenever he developed local or systemic discomfort. For every 
patient separate podophyllin containers was used.  
2.  LIQUID NITROGEN: Liquid nitrogen applied by cotton 
wool swab on orange sticks dipped in liquid nitrogen on the warts once 
in alternative Thursdays, by double freeze – thaw cycles technique 
which consisted of one sitting. Like this, a maximum of 6 sittings were 
applied. Tissues were held frozen for 15 and 30 seconds. Adequacy of 
freezing was assessed by formation of ice ball 1-2 mm beyond the 
periphery of the lesion. If there was no problem, patients were instructed 
to review on the alternative Thursdays  for 7 sittings from the starting 
date of the treatment and patients were instructed to attend the STD 
OPD whenever he developed local or systemic discomfort. For every 
patient and for every cycle,   separate sticks were used.  
 3.  80% W/V  TRICHLOROACETIC ACID  SOLUTION: 
80% w/v trichloroacetic acid in water was applied once on every 
Tuesdays for a maximum of 6 weeks, by using wooden applicator stick 
with the surrounding skin protected with zinc oxide cream. Patients 
were reviewed on every Tuesdays if there was no problem. Patients 
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were instructed to attend the STD OPD whenever he developed local or 
systemic discomfort. For every patient, separate sticks was used.  
4.  5 % IMIQUIMOD: 5% imiquimod cream was applied by 
the patient himself as a thin layer of cream (by using digits) and three 
times in a week (Wednesday/Friday/Sunday) preferably at night times 
for a maximum of 10 weeks. The first application was done in the OPD 
itself. On Wednesdays 3 sachets (5%imiquimod cream) was given. Each 
sachet for every other day. Patients were instructed to wash imiquimod 
applied area with soap and water after 10 hours and patients were 
reviewed once every Wednesday if there was no problem. Patients were 
instructed to attend the STD OPD whenever he developed local or 
systemic discomfort.  
 5. ELECTROCAUTERY: 1 hr after the application of topical 
EMLA, electro cautery was done. Patients with GRADE A response to 
treatment were considered as treatment success. A patient whose 
responses to treatment were GRADE B, GRADE C or development of 
any local but not acceptable side effects or systemic side effects; for 
those patients therapeutic modality was changed. Patients, whose 
treatment was changed during the course of treatment, were considered 
as treatment failed. 
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RESULTS 
TABLE 1  
TOTAL PREVALENCE OF ANOGENITAL WART AND HIV 
INFECTION AMONG STD MALE OPD ATTENDEES FOR THE 
PERIOD OF JUNE 2007 – MAY 2009 
• The Prevalence of Anogenital wart among STD male OPD 
attendees– 1.91% 
• The Prevalence of HIV infection among STD male OPD 
attendees of– 2.69% 
TABLE 2 
PREVALENCE OF WART IN HIV INFECTED AND HIV NON 
INFECTED   
• The Prevalence of HIV infected with Anogenital warts among 
STD male OPD attendees  - 13.14% 
• The Prevalence of HIV Non infected with Anogenital warts 
among  STD male OPD attendees   -1.60% 
•  Prevalence of genital wart is 8.2 times higher among HIV 
infected patients when compared to HIV Non infected patients. 
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                                        TABLE 3 
COMPARISON OF PROPORTION OF TREATMENT 
RESPONSE AT THE END OF THE TREATMENT AMONG 
DIFFERENT STUDY 
• Complete clearance of warts (GRADE A response) is highest 
among study Group V (ELETROCAUTERY) followed by study 
group II, I, III and IV. 
 
TABLE 4 
 COMPARISON OF PROPORTION OF TREATMENT 
RESPONSE AFTER 3 MONTHS AMONG DIFFERENT STUDY 
GROUPS 
• Recurrence rate after 3 month of treatment is lowest among 
Group V followed by Group II, IV, I and III. 
• Complete clearance after 3 month of treatment is highest among 
Group V followed by Group II, III, I and IV 
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                                                  TABLE 5 
COMPARISON OF PROPORTION OF SIDE EFFECTS AMONG 
DIFFERENT STUDY GROUPS  
• Patients complete their treatment without side effects seen highest 
among study group IV followed by group II, III, V and I. 
• Patients complete their treatment with local acceptable side 
effects seen highest among study group I followed by group III, 
V, II and IV. 
• Patients complete their treatment with local but not acceptable 
side effects seen only with group II.  
TABLE 6 
COMPARISON OF PROPORTION OF HIV STATUS AMONG 
DIFFERENT STUDY GROUPS 
• Almost all study group had equal number of HIV infected cases. 
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                                       TABLE 7 
COMPARISON OF PROPORTION OF RESPONSE TO 
TREATMENT AND HIV STATUS IN GROUP I  
• Complete clearance of the warts (Grade A response) with 
podophyllin (Group I) among HIV infected and HIV Non infected 
cases were 80% and 77.8% respectively. i.e almost equal. 
 
TABLE 8 
COMPARISON OF PROPORTION OF RESPONSE TO 
TREATMENT AND HIV STATUS IN GROUP II  
• Complete clearance of the warts (Grade A response) with liquid 
nitrogen (Group II) among HIV infected and HIV Non infected 
were 75% and 81.3% respectively. i.e almost equal.  
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TABLE 9 
COMPARISON OF PROPORTION OF RESPONSE TO 
TREATMENT AND HIV STATUS IN GROUP III  
• Complete clearance of warts (Grade A response) with 80%TCA 
(Group III) among HIV infected and HIV Non infected cases 
were 100% and 68.8% respectively. 
 
TABLE 10 
COMPARISON OF PROPORTION OF RESPONSE TO 
TREATMENT AND HIV STATUS IN GROUP IV  
• Complete clearance of the warts (Grade A response) with 
5%imiquimod (Group IV)among HIV infected and  HIV Non 
infected cases were 50% and 45.5% respectively. i.e,almost equal.  
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TABLE 11 
COMPARISON OF PROPORTION OF RESPONSE TO 
TREATMENT AND HIV STATUS IN GROUP V  
• Complete clearance of the warts (Grade A response) with ECT 
(Group V) among HIV infected and HIV Non infected cases were 
75% and 100% respectively.  
 
TABLE 12 
COMPARISON OF PROPORTION OF RESPONSE TO 
TREATMENT AT THE END OF 3 MONTHS AND HIV STATUS IN 
GROUP I  
• Clearance rate after 3 month of treatment with podophyllin 
(Group I) among HIV infected and HIV Non infected cases were 
40% and 44.4% respectively. i.e,  almost equal. 
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TABLE 13 
COMPARISON OF PROPORTION OF RESPONSE TO 
TREATMENT AT THE END OF 3 MONTHS AND HIV STATUS 
IN GROUP II  
• Clearance rate after 3 month of treatment with liquid 
nitrogen(Group II) among HIV infected and HIV Non infected 
cases were 25% and 56.3% respectively. 
 
TABLE 14 
COMPARISON OF PROPORTION OF RESPONSE TO 
TREATMENT AT THE END OF 3 MONTHS AND HIV STATUS 
IN GROUP III  
• Clearance rate after 3 month of treatment with 80%TCA(Group 
III) among HIV infected and HIV Non infected cases were 50% 
and 46.7%respectively.i.e, almost equal. 
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TABLE 15 
COMPARISON OF PROPOFORTION OF RESPONSE TO 
TREATMENT AT THE END OF 3 MONTHS AND HIV STATUS 
IN GROUP IV  
• Clearance rate after 3 month of treatment with5%imiquimod 
(Group IV ) among HIV infected and HIV Non infected cases 
were 50% and 10% respectively. 
TABLE 16 
COMPARISON OF PROPORTION OF RESPONSE TO 
TREATMENT AT THE END OF 3 MONTHS AND HIV STATUS 
IN GROUP V  
• Clearance rate after 3 month of treatment with ECT(Group V) 
among HIV infected and HIV Non infected cases were 50% and 
93.8% respectively. 
TABLE 17 
COMPARISON OF MEAN RESPONSE DURATION AMONG 
DIFFERENT STUDY GROUPS  
• Among all study groups, ECT (Group V) takes minimal 
duration(1.8  ± 0.8)  of time for the complete clearance of the 
warts.  
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RESULTS 
 
TABLE 1   
TOTAL PREVALENCE OF ANOGENITAL WART AND HIV INFECTION 
Condition Total Number Number Positive Prevalence (%) 
Wart 6504 124 1.91 
HIV 6504 175 2.69 
 
 
TABLE 2 
PREVALENCE OF WART IN HIV INFECTED AND NON HIV 
INFECTED  CASES 
 
 
Total 
Number 
Number 
Positive 
Prevalence (%)  
P-Value* 
HIV +ve 175 23 13.14  
<0.0001 (Sig.)HIV -ve 6329 101 1.60 
*Fisher’s Exact Test (2-tailed) was used to calculate the P-value 
INFERENCE 
  
The prevalence of wart in HIV infected cases  (13.14%) is 
significantly higher than in Non HIV infected  cases  (1.60%)   
(P<0.0001).  
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TABLE 3 
COMPARISON OF PROPORTION OF TREATMENT 
RESPONSE AT THE END OF THE TREATMENT AMONG 
DIFFERENT STUDY GROUPS  
 
Rx 
Response 
Group I Group II Group III Group IV Group V P-
value* No % No % No % No % No % 
Grade - A 18 78.3 16 80.0 15 75.0 7 46.7 19 95.0  
0.03 
(Sig.) 
Grade - B 1 4.3 3 15.0 4 20.0 6 40.0 1 5.0 
Grade - C 4 17.4 1 5.0 0 0.0 1 6.7 0 0.0 
DCT 0 0.0 0 0.0 1 5.0 1 6.7 0 0.0 
*Chi-square test was used to calculate the P-Value 
 
INFERENCE 
There is significant association between response to treatment and 
different study groups (P=0.03). That is, the distribution of response to 
treatment is not similar in all study groups.  
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TABLE 4 
COMPARISON OF PROPORTION OF TREATMENT 
RESPONSE AFTER 3 MONTHS AMONG DIFFERENT STUDY 
GROUPS  
 
Rx 
Response  
Group I Group II Group III Group IV Group V P-
value* 
No % No % No % No % No % 
FF 1 4.3 1 5.0 0 0.0 0 0.0 1 5.0  
0.09 
(N.S.) NOR 10 43.5 10 50.0 9 47.4 3 21.4 17 85.0 
RO 7 30.4 5 25.0 6 31.6 4 28.6 1 5.0 
TC 5 21.7 4 20.0 4 20.0 7 50.0 1 5.0 
*Chi-square test was used to calculate the P-Value 
 
INFERENCE 
  
 There is no significant association between response to 
treatment at the end of 3 months and different study groups (P=0.09). 
That is, the distribution of response to treatment at the end of 3 months 
is almost similar in all study groups.  
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TABLE 5 
COMPARISON OF PROPORTION OF SIDE EFFECTS AMONG 
DIFFERENT STUDY GROUPS  
 
Side 
effect  
Group I Group II Group III Group IV Group V  
P-
value* No % No % No % No % No % 
LA+ 20 87.0 11 55.0 16 80.0 7 50.0 16 80.0  
0.01 
(Sig.) LNA+ 0 0.0 3 15.0 0 0.0 0 0.0 0 0.0 
NIL 3 13.0 6 30.0 4 20.0 7 50.0 4 20.0 
*Chi-square test was used to calculate the P-Value 
INFERENCE 
  
 There is significant association between side effect and 
different study groups (P=0.01). That is, the distribution of side effect is 
not similar in all five study groups.  
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TABLE 6 
COMPARISON OF PROPORTION OF HIV STATUS AMONG 
DIFFERENT STUDY GROUPS  
 
HIV 
status  
Group I Group II Group III Group IV Group V P-
value* No % No % No % No % No % 
NR 18 78.3 16 80.0 16 80.0 11 73.3 16 80.0 0.99 
(N.S.) 
R 5 21.7 4 20.0 4 20.0 4 26.7 4 20.0 
*Chi-square test was used to calculate the P-Value 
INFERENCE 
 There is no significant association between HIV status and 
different study groups (P=0.99). That is, the distribution of HIV status is 
almost similar in all five study groups.  
TABLE 7 
COMPARISON OF PROPORTION OF RESPONSE TO 
TREATMENT AND HIV STATUS IN GROUP I  
 
Rx Response HIV - NR  HIV – R P-value* 
No % No % 
Grade - A 14 77.8 4 80.0  
0.86 (N.S.) Grade - B 1 5.6 0 0.0
Grade - C 3 16.7 1 20.0
 *Chi-square test was used to calculate the P-Value 
 
INFERENCE 
  There is no significant association between response to treatment 
and HIV status in Group I (P=0.86). That is, the distribution of response 
to treatment in both HIV status is almost similar in Group I. 
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TABLE 8 
COMPARISON OF PROPORTION OF RESPONSE TO TREATMENT 
AND HIV STATUS IN GROUP II  
 
Rx Response 
HIV - NR HIV – R 
P-value* 
No % No % 
Grade - A 13 81.3 3 75.0  
0.74 (N.S.) Grade - B 2 12.5 1 25.0
Grade - C 1 6.3 0 0.0
*Chi-square test was used to calculate the P-Value 
INFERENCE 
 There is no significant association between response to treatment and 
HIV status in Group II (P=0.74). That is, the distribution of response to 
treatment in both HIV status is almost similar in Group II. 
TABLE 9 
COMPARISON OF PROPORTION OF RESPONSE TO TREATMENT 
AND HIV STATUS IN GROUP III  
 
Rx Response 
HIV - NR HIV – R 
P-value* 
No % No % 
Grade - A 11 68.8 4 100.0  
 
0.44 (N.S.) 
Grade - B 4 25.0 0 0.0
Grade - C 0 0.0 0 0.0
DCT 1 6.3 0 0.0
*Chi-square test was used to calculate the P-Value 
INFERENCE 
There is no significant association between response to treatment 
and HIV status in Group III (P=0.44). That is, the distribution of 
response to treatment in both HIV status is almost similar in Group III. 
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TABLE 10 
COMPARISON OF PROPORTION OF RESPONSE TO 
TREATMENT AND HIV STATUS IN GROUP IV  
 
Rx Response 
HIV - NR HIV – R 
P-value* 
No % No % 
Grade - A 5 45.5 2 50.0  
 
0.83 (N.S.) 
Grade - B 4 36.4 2 50.0
Grade - C 1 9.1 0 0.0
DCT 1 9.1 0 0.0
*Chi-square test was used to calculate the P-Value 
INFERENCE 
There is no significant association between response to treatment 
and HIV status in Group IV (P=0.83). That is, the distribution of 
response to treatment in both HIV status is almost similar in Group IV. 
 
TABLE 11 
COMPARISON OF PROPORTION OF RESPONSE TO 
TREATMENT AND HIV STATUS IN GROUP V  
 
Rx Response HIV - NR HIV – R P-value# No % No % 
Grade - A 16 100.0 3 75.0  
0.20 (N.S.) 
Grade - B 0 0.0 1 25.0
Grade - C 0 0.0 0 0.0
#Fisher’s Exact test (2-tailed) was used to calculate the P-Value 
INFERENCE 
  There is no significant association between response to treatment and 
HIV status in Group V (P=0.20). That is, the distribution of response to 
treatment in both HIV status is almost similar in Group V. 
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TABLE 12 
COMPARISON OF PROPORTION OF RESPONSE TO TREATMENT 
AT THE END OF 3 MONTHS AND HIV STATUS IN GROUP I  
 
Rx Response 
HIV - NR HIV – R 
P-value* 
No % No % 
FF 1 5.6 0 0.0  
 
0.92 (N.S.) 
NOR 8 44.4 2 40.0
RO 5 27.8 2 40.0
TC 4 22.2 1 20.0
       *Chi-square test was used to calculate the P-Value 
INFERENCE 
There is no significant association between response to treatment 
at 3 months and HIV status in Group I (P=0.92). That is, the distribution 
of response to treatment in both HIV status is almost similar in Group I. 
TABLE 13 
COMPARISON OF PROPORTION OF RESPONSE TO 
TREATMENT AT THE END OF 3 MONTHS AND HIV STATUS 
IN GROUP II  
Rx Response HIV - NR HIV – R P-value* No % No % 
FF 1 6.3 0 0.0  
0.53 (N.S.) NOR 9 56.3 1 25.0
RO 3 18.8 2 50.0
TC 3 18.8 1 25.0
*Chi-square test was used to calculate the P-Value 
INFERENCE 
There is no significant association between response to treatment 
at 3 months and HIV status in Group II (P=0.53). That is, the 
distribution of response to treatment in both HIV status is almost similar 
in Group II. 
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TABLE 14 
COMPARISON OF PROPORTION OF RESPONSE TO TREATMENT 
AT THE END OF 3 MONTHS AND HIV STATUS IN GROUP III  
 
Rx Response 
HIV - NR HIV – R 
P-value* 
No % No % 
FF 0 0.0 0 0.0  
 
0.58 (N.S.) 
NOR 7 46.7 2 50.0
RO 4 26.7 2 50.0
TC 4 26.7 0 0.0
*Chi-square test was used to calculate the P-Value 
INFERENCE 
There is no significant association between response to treatment at 3 
months and HIV status in Group III (P=0.58). That is, the distribution of 
response to treatment in both HIV status is almost similar in Group III. 
TABLE 15 
COMPARISON OF PROPORTION OF RESPONSE TO TREATMENT 
AT THE END OF 3 MONTHS AND HIV STATUS IN GROUP IV  
 
Rx Response HIV - NR  HIV – R  
P-value* No % No % 
FF 0 0.0 0 0.0  
0.23 (N.S.) NOR 1 10.0 2 50.0
RO 4 40.0 0 0.0
TC 5 50.0 2 50.0
                        *Chi-square test was used to calculate the P-Value 
INFERENCE 
There is no significant association between response to treatment at 3 
months and HIV status in Group IV (P=0.23). That is, the distribution of 
response to treatment in both HIV status is almost similar in Group IV. 
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TABLE 16 
COMPARISON OF PROPORTION OF RESPONSE TO TREATMENT 
AT THE END OF 3 MONTHS AND HIV STATUS IN GROUP V  
 
Rx Response 
HIV - NR  HIV – R 
P-value* 
No % No % 
FF 0 0.0 1 25.0  
 
0.03 (Sig.) 
NOR 15 93.8 2 50.0
RO 1 6.3 0 0.0
TC 0 0.0 1 25.0
*Chi-square test was used to calculate the P-Value 
INFERENCE 
There is significant association between response to treatment at 3 months 
and HIV status in Group V (P=0.03). That is, the distribution of response to 
treatment in both HIV status is not similar in Group V. 
TABLE 17 
COMPARISON OF MEAN RESPONSE DURATION AMONG 
DIFFERENT STUDY GROUPS 
 
Group Mean ± S.D. Overall P-value* 
Significant 
groups at 5% 
level# 
I 4.0  ± 1.6 
<0.0001 
(Sig.) 
I vs. II, IV, V. 
II vs. III, V. 
III vs. IV, V. 
IV vs. V. 
 
II 8.4  ± 1.9 
III 5.0  ± 0.9 
IV 9.1  ± 1.6 
V 1.8  ± 0.8
 
*Kruskal-Wallis One Way ANOVA was used to calculate the P-value 
#Mann-Whitney U test followed by Bonferroni correction procedure was employed 
to identify the significant groups at 5% level 
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INFERENCE 
¾ The mean duration for treatment response is highest in Group 
IV (9.1  ± 1.6) followed by Group II (8.4  ± 1.9), Group III (5.0  
± 0.9), Group I (4.0  ± 1.6) and the lowest in Group V (1.8  ± 
0.8). 
¾ The mean duration for treatment response in Group IV (9.1  ± 
1.6) is significantly higher than Group I (1.8  ± 0.8), Group III 
(5.0  ± 0.9) and Group V (1.8  ± 0.8) (P<0.05). 
¾ Also The mean duration for treatment response in Group II (8.4  
± 1.9) is significantly higher than Group III (5.0  ± 0.9) and 
Group V (1.8  ± 0.8) (P<0.05). 
¾ Further, The mean duration for treatment response in Group I 
(1.8  ± 0.8) and Group III (5.0  ± 0.9) are significantly higher 
than Group V (1.8  ± 0.8) (P<0.05). 
¾ However, no other contrasts are statistically significant 
(P>0.05). 
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Figure No. 1 
PREVALENCE OF WART AND HIV 
 
 
Figure No. 2 
PREVALENCE OF WART IN HIV+VE AND HIV-VE CASES 
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Figure No. 3 
 
PROPORTION OF TREATMENT RESPONSE AT THE END OF 
THE TREATMENT IN DIFFERENT STUDY GROUPS 
 
 
Figure No. 4 
PROPORTION OF TREATMENT RESPONSE AFTER 3 
MONTHS IN DIFFERENT STUDY GROUPS 
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Figure No. 5 
PROPORTION OF SIDE EFFECTS IN DIFFERENT STUDY GROUPS 
 
Figure No. 6 
PROPORTION OF HIV STATUS IN DIFFERENT STUDY 
GROUPS 
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Figure No. 7 
PROPORTION OF RESPONSE TO TREATMENT IN HIV-NR AND 
HIV-R CASES IN GROUP I 
 
Figure No. 8 
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PROPORTION OF RESPONSE TO TREATMENT IN HIV-NR AND 
HIV-R CASES IN GROUP II 
 
Figure No. 9 
PROPORTION OF RESPONSE TO TREATMENT IN HIV-NR AND 
HIV-R CASES IN GROUP III 
 
Figure No. 10 
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PROPORTION OF RESPONSE TO TREATMENT IN HIV-NR AND 
HIV-R CASES IN GROUP IV 
 
 
Figure No. 11 
PROPORTION OF RESPONSE TO TREATMENT IN HIV-NR AND 
HIV-R CASES IN GROUP V 
 
92 
 
Figure No. 12 
PROPORTION OF RESPONSE TO TREATMENT AT THE 
END OF 3 MONTHS IN HIV-NR AND HIV-R CASES IN 
GROUP I 
 
 
 
Figure No. 13 
 
PROPORTION OF RESPONSE TO TREATMENT AT THE 
END OF 3 MONTHS IN HIV-NR AND HIV-R CASES IN 
GROUP II 
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Figure No. 14 
PROPORTION OF RESPONSE TO TREATMENT AT THE END OF 3 
MONTHS IN HIV-NR AND HIV-R CASES IN GROUP III 
 
Figure No. 15 
PROPORTION OF RESPONSE TO TREATMENT AT THE END OF 3 
MONTHS IN HIV-NR AND HIV-R CASES IN GROUP IV 
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Figure No. 16 
PROPORTION OF RESPONSE TO TREATMENT AT THE END 
OF 3 MONTHS IN HIV-NR AND HIV-R CASES IN GROUP V 
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Figure No. 17 
MEAN RESPONSE DURATION IN DIFFERENT STUDY GROUPS 
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CONDYLOMATA ACUMINATA 
 
 
 
RESOLVING GENITAL WARTS (TREATED WITH 
PODOPHYLLIN) 
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GENITAL WARTS (Inner lining of prepuce)  
 
 
 
GENITAL WARTS IN PREPUTIAL CAVITY 
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GENITAL WARTS IN INNER LINING OF PREPUCE 
 
 
 
 
GENITAL WARTS IN THE GROIN REGION 
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PERIANAL WARTS 
 
 
 
CONDYLOMATA ACUMINATA 
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GENITAL WARTS (PAPULAR TYPE) 
 
 
GENITAL WARTS (ROOT OF THE PENIS) 
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DISCUSSION 
 
This study highlights the prevalence of Anogenital wart, 
prevalence of HIV infection and different treatment modalities and 
treatment responses on exophytic anogenital wart among the patients 
who attended STD male OPD. 
During the period of 2 yrs from June 2007 – May 2009, total 
number of patients who attended STD male OPD were 6504 which 
included both NON HIV and HIV infected individuals. Out of 6504 
patients 1.91% and 2.69% were infected with genital wart and HIV 
respectively.  A recent study shows the prevalence of genital warts in 
India to be  between 5.1% to 25.2% of STD patients.        
Among the male NON HIV infected individuals 1.60% of 6329 
patients had genital wart and among the male HIV infected individuals 
13.14% of 175 patients had genital wart. Prevalence of genital wart was 
8.2 times higher among HIV infected patients when compared to HIV 
Non infected patients. This was comparable with a report by Arora et al 
incidence of Anogenital warts have increased from 7.2% to 8.8% among 
the HIV infected patients over a period of 5 years.  
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98 (79%) of 124 genital wart patients were enrolled in the 
randomised open clinical trial on different treatment modalities and 
treatment response on exophytic genital wart.  Among the 98 patients 
with genital wart 23, 20, 20, 15 and 20 patients were treated with 
podophyllin(groupI),liquidnitrogen(groupII) trichloroaceticacid 
(groupIII),imiquimod(groupIV) and electrocautery (groupV) 
respectively and their grade A response(complete clearance of wart) at 
the end of the treatment were78.3%, 80%, 75%, 46.7% and 95% 
respectively. Study GroupV shows good response followed by groupII, 
groupI, groupIII, groupIV in descending order. Their recurrence rate 
after 3 months of treatment were 30.4%,25%,31.6%,28.6% and 5% 
respectively. Once again it shows study groupV have good response 
followed by groupII, groupIII, groupI and groupIV in descending order. 
This study shows electrocautery therapy and cryotherapy are more 
efficacious than other modalities.  
On comparing the side effects, irrespective of their clearance rate 
in all study group most of them developed local acceptable side effects 
(70%). Few patients complete their treatment without any side effects. 
But 15% of patients in study group II show local but not acceptable side 
effects whereas other study group did not develop local but not 
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acceptable side effects.  None of the study group developed systemic 
side effects.  
This study was comparable with the study done by Beutner KR, 
Wiley D J et at. In their study, they compared the efficacy of 
podophyllin, liquid nitrogen, trichloroacetic acid and electrocautery. As 
per their study, efficacy of therapy at the end of the treatment and 
recurrence rate  were 32-79%, 63-88%, 50-81%, 93-94% and 11-65%, 
0-39%, 36%,24% respectively. According to their study electrocautery 
and cryotherapy were more efficacious than other modalities.       
When compared with a randomised clinical trial by K M Stone, T 
M Becker, A Hadgu, S J Kraus on Treatment of external genital warts 
using podophyllin, cryotherapy, and electro desiccation the following 
were noted. In their study, four hundred and fifty patients were enrolled 
into a randomised clinical trial in a public sexually transmitted diseases 
clinic to evaluate the efficacy of podophyllin, cryotherapy, and electro 
desiccation for treatment of external genital warts. Complete clearance 
of warts was observed in 41%, 79% and 94% of patients who received 
up to six weekly treatments of podophyllin, cryotherapy and electro 
desiccation respectively. Relapses occurred in 25% of all patients, 
yielding 3 month clearance rates of 17%, 55% and 71% for podophyllin, 
cryotherapy and electro desiccation  respectively. Wart volume and 
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duration did not influence treatment outcome. Electro desiccation and 
cryotherapy were more effective than podophyllin for the treatment of 
external genital warts.                 
Statistically, there is a significant association between response to 
treatment and different study groups (P=0.03). That is, the distribution 
of response to treatment is not similar in all study groups but there is no 
significant association between response to treatment at the end of 3 
months and different study groups (P=0.09). That is, the distribution of 
response to treatment at the end of 3 months is almost similar in all 
study groups. There is significant association between side effect and 
different study groups (P=0.01). That is, the distribution of side effect is 
not similar in all five study groups.  
In this study, all study groups had HIV patients almost equally. 
When compared to the treatment response at the end of the treatment 
among  HIV Non  infected and HIV infected patients  in study group I 
shows response to treatment in was almost similar that is complete 
clearance of wart HIV Non infected and HIV infected  were 77.8% and 
80% respectively. In the study, group II showed almost similar response 
to treatment that is complete clearance of wart in both HIV Non infected 
and HIV infected were 81.3% and 75% respectively. Similarly study 
groupIII, IV, V showed almost similar response to treatment at the end 
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of treatment for both HIV Non infected and HIV infected patients.  But 
treatment response after 3 month in both HIV Non infected and HIV 
infected  patients  were almost similar in all study group except study 
group V (ECT) where the complete clearance of the wart at end of 3 
month were 93.8% among HIV non reactive and 50% among HIV 
infected patient which is statistically significant.(p =0.03) 
 The mean duration for treatment response is highest in Group 
IV (9.1 ± 1.6) followed by Group II (8.4 ± 1.9), Group III (5.0 ± 0.9), 
Group I (4.0 ± 1.6) and the lowest in Group V (1.8 ± 0.8). 
 The mean duration for treatment response in Group IV (9.1 ± 
1.6) is significantly higher than Group I (1.8 ± 0.8), Group III (5.0 ± 0.9) 
and Group V (1.8 ± 0.8) (P<0.05). 
 Also the mean duration for treatment response in Group II (8.4 
± 1.9) is significantly higher than Group III (5.0 ± 0.9) and Group V (1.8 
± 0.8) (P<0.05). 
 Further, The mean duration for treatment response in Group I 
(1.8 ± 0.8) and Group III (5.0 ± 0.9) are significantly higher than Group 
V (1.8 ± 0.8) (P<0.05). 
It shows that study group V had favorable outcome with in short 
period followed by group I and III.                
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CONCLUSION 
 
 
This study was conducted for a period of 2 years from June 2007 
to May 2009 in those patients who attended STD male OPD in Institute 
of Venereology, Madras Medical College,  Chennai. This study showed 
the prevalence of genital warts among the STD male OPD attendees to 
be 1.91%. The prevalence of HIV infection among STD male OPD 
attendees was 2.69%. The prevalence of genital warts was 8.2 times 
higher among HIV infected patients than HIV non infected patients. 
Among all study groups, study group V and study group II shows more 
efficacy than other treatment modalities i.e electrocautery therapy and 
liquid nitrogen therapy respectively. But while compared to liquid 
nitrogen, electrocautery showed low recurrence rate with minimum 
number of applications to obtain maximum response with acceptable 
level of side effects.  When compared to treatment response at the end of 
treatment among HIV Non infected and HIV infected individuals shows 
there is no statistical significance between these two for all study 
groups. Similarly treatment response after 3 months showed statistically 
insignificant difference except for study group V(electrocautery).  Most 
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of the patients developed local acceptable side effect during the course 
of treatment but it resolved on its own.  
Note :  
 I would like to mention that due to the constraints in total no of 
cases attended and selected for the study, the result may not be fully 
conclusive, therefore further detailed evaluation and research may be 
necessary to documented conclusion.  
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MC-PREVALENCE OF HPV INFECTION AND HIV 
INFECTION 
 
MONTH 
NON 
HIV 
CASES 
TOTAL NO. 
OF WART 
IN HIV‐VE 
CASES 
TOTAL 
NO. 
OF HIV 
CASES 
TOTAL NO. 
OF WART 
IN HIV +VE 
CASES 
TOTAL 
NO.OF  
CASES IN 
STD OPD 
TOTAL NO. 
OF WART 
CASES 
Jun‐07  257  2  4  1  261  3 
Jul‐07  244  2  4  1  248  3 
Aug‐07  277  4  12  3  289  7 
Sep‐07  256  1  0  nil  256  1 
Oct‐07  288  2  15  4  303  6 
Nov‐07  258  3  7  2  265  5 
Dec‐07  223  5  3  1  226  6 
Jan‐08  274  5  9  1  283  6 
Feb‐08  296  4  5  nil  301  4 
Mar‐08  248  4  7  nil  255  4 
Apr‐08  276  7  8  nil  284  7 
May‐08  261  5  11  1  272  6 
Jun‐08  262  10  8  nil  270  10 
Jul‐08  262  10  8  4  270  14 
Aug‐08  359  5  4  nil  363  05 
Sep‐08  280  6  14  nil  294  06 
Oct‐08  225  1  4  nil  229  01 
Nov‐08  242  5  15  1  257  06 
Dec‐08  285  5  3  nil  288  05 
Jan‐09  270  7  11  nil  281  07 
Feb‐09  258  2  4  nil  262  02 
Mar‐09  276  3  2  nil  278  03 
Apr‐09  255  3  7  1  262  04 
May‐09  197  nil  10  3  207  03 
TOTAL  6329  101  175  23  6504  124 
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PROFORMA 
 
CASE NO   : 
NAME OF THE PATIENT : 
AGE/SEX   : 
MALE STD OP NO  : 
OCCUPATION & INCOME: 
STD CLINIC NO  : 
ADDRESS    : 
MARITAL STATUS : MARRIED (MD) /UNMARRIED (UM)/  WIDOWER 
(W)  
PRESENTING COMPLAINTS: 
TREATMENT TAKEN FOR PRESENTING ILLNESS: 
PAST HISTORY: Previous STDs  and Treatment taken/Similar illness & 
Details/Diabetes/Hypertension/Surgeries/Blood Transfusion/TB/ Asthma  
 
CONTACT HISTORY:  
Partner Name/ Occupation/History and Investigation                                            
 
SEXUAL HISTORY: 
 
SEXUAL ORIENTATION: HeteroSexuals(HT)/Homosexuals(H)/Bisexual(BI)  
 
SEXUAL CONTACT: Premarital Contact(PMC)/Marital 
Contact(MC)/Extramarital Contact(EMC)/Last Contact(LC) 
 
RECENT EXPOSURE: With Known Person(K)Or Unknown 
Person(UK)/Protected (P)/UnProtected (UP) Sex/Paid (PD) /Not Paid (NPD) 
 
PERSONAL HISTORY: Alcohol / Smoking/ Betelnut Chewing/ Drug Abuse/ 
Blood Transfusion 
GENERAL EXAMINATION (NAD –NO ABNORMALITY DETECTED):  
PR/BP/Anemia/Jaundice/Clubbing/Lymphadenopathy/Cyanosis/CVS/ 
RS/Abdomen/CNS 
 
GENITAL EXAMINATION: 
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Uncircumcised/Circumcised 
 
Penile ulcer /penile scar/urethral discharge /sub preputial discharge/urethral meatus 
Inguinal lymph nodes/skin and mucous membrane/ bone & joints 
 
SITE OF WART - Inner Lining Of Prepuce/Glans Penis/Corona Glandis/Shaft Of 
The  Penis/Pubis/Perineum/Perianal Region/Frenelum 
 
TYPE OF WART:  
Condylomata Acuminata(A)/ Papular Wart(PW)/ Keratotic Wart(KW)/ Flat Topped 
Papule(FP)Per Rectal Examination 
 
INVESTIGATION :  
 
URINE:  Albumin/Sugar/Deposits 
 
BLOOD: Complete Blood Count -Normal Value (NV) /Abnormal Value (AB) 
    Liver Function Test -Normal Value (NV)/Abnormal Value (AB) 
    Renal Function Test -Normal Value (NV)/Abnormal Value (AB) 
SEROLOGICAL: VDRL – Reactive(R)/Nonreactive (NR) 
                              ELISA FOR HIV-Reactive(R)/Nonreactive (NR) 
                              CD 4+ COUNT 
  
PROCTOSCOPY/MEATOSCOPY: 
 
BIOPSY:                       
TREATMENT GIVEN :  
GROUP I   - Patients treated with 20% podophyllin 
GROUP II  - Patients treated with liquid nitrogen 
GROUP III - Patients treated with trichloroacetic acid 
GROUP IV - Patients treated with imiquimod 
GROUP V - Patients treated with electro cautery 
 
TREATMENT RESPONSE :  
    
GRADE A -  Lesions  Completely  Resolved 
GRADE B - Lesions reduced in size 
GRADE C - Lesions not responding to treatment even after completion  
  of treatment. 
DCT  -          Treatment Discontinued 
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SIDE EFFECTS : 
 
 LA+      -  Local acceptable side effect(itching, burning, erythema, pain, 
tenderness and erosion) 
 
LNA+    -  Local but not acceptable side effects (swelling, ulcer, necrotising 
balanoposthitis and phimosis) 
 
NIL       -  No side effect 
 
S +       -  Systemic side effects: dizziness, lethargy, precoma, nausea, vomiting, 
abdominal pain, respiratory distress and cold clammy skin. 
Reversible bone marrow suppression with thrombocytopenia and 
leucopenia 
 
RECURRENCE & FOLLOW UP: (EVERY 3 MONTH) 
 
FF - Follow up failed 
RO - Recurrence 
NOR  -  No recurrence 
TC -  Treatment changed  
                                                                                      
CLINICAL PHOTOS:    
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ABBREVIATION IN TABLES AND  
MASTER CHART 
 
 
A  -  CONDYLOMA ACUMINATE 
KW  - KERATOTIC WART 
PW  - PAPULAR WART 
FP  -  FLAT TOPPED PAPULAR WART 
NR  -  NON REACTIVE 
R  -  REACTIVE 
GROUP I - PATIENTS TREATED WITH 20% PODOPHYLLIN 
GROUP II -  PATIENTS TREATED WITH LIQUID NITROGEN 
GROUP III - PATIENTS TREATED WITH TRICHLOROACETIC ACID 
GROUP IV -  PATIENTS TREATED WITH IMIQUIMOD 
GROUP V - PATIENTS TREATED WITH ELECTRO CAUTERY 
GRADE A  - LESIONS COMPLETELY RESOLVED. 
GRADE B  -  LESIONS REDUCED IN SIZE BUT NOT  
   COMPLETELY RESOLVED. 
GRADE C  -  LESIONS NOT RESPONDING TO TREATMENT EVEN 
   AFTER COMPLETION OF     TREATMENT. 
DCT        - TREATMENT DISCONTINUED. 
RO  - RECURRENCE 
NOR  - NO RECURRENCE 
TC  -  TREATMENT CHANGED 
FF  -  FOLLOW UP FAILED 
LA+   -  LOCAL ACCEPTABLE SIDE EFFECT(ITCHING ,  
   BURNING, ERYTHEMA, PAIN, TENDERNESS AND  
   EROSION) 
LNA+   -  LOCAL BUT NOT ACCEPTABLE SIDE EFFECTs 
   (SWELLING, ULCER, NECROTISING    
   BALANOPOSTHITIS AND PHIMOSIS) 
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NIL  -  NO SIDE EFFECT 
Md   - MARRIED 
UM  -  UNMARRIED 
W  -  WIDOW 
HT  - HETEROSEXUAL 
H   - HOMOSEXUAL 
Bi  -  BISEXUAL 
UK  -  UNKNOWN 
K  -  KNOWN 
UP  - UNPROTECTED 
P  - PROTECTED 
NPD  - NOT PAID 
PD  -  PAID 
MC  -  MARITAL CONTACT 
NAD  -  NO ABNORMALITY DETECTED 
NV  -  NORMAL VALUES 
AB  -  ABNORMAL VALUES 
VDRL  - VENERAL DISEASE RESEARCH LABORATORY 
LFT  -  LIVER FUNCTION TEST 
RFT  -  RENAL FUNCTION TEST 
CBC  -  COMPLETE BLOOD COUNT 
MC-PREVALENCE OF HPV INFECTION AND HIV INFECTION 
 
MONTH 
NON 
HIV 
CASES 
TOTAL NO. 
OF WART IN 
HIV‐VE 
CASES 
TOTAL NO.
OF HIV 
CASES 
TOTAL NO. 
OF WART IN 
HIV +VE 
CASES 
TOTAL 
NO.OF  
CASES IN 
STD OPD 
TOTAL NO. 
OF WART 
CASES 
Jun‐07  257  2  4  1  261  3 
Jul‐07  244  2  4  1  248  3 
Aug‐07  277  4  12  3  289  7 
Sep‐07  256  1  0  nil  256  1 
Oct‐07  288  2  15  4  303  6 
Nov‐07  258  3  7  2  265  5 
Dec‐07  223  5  3  1  226  6 
Jan‐08  274  5  9  1  283  6 
Feb‐08  296  4  5  nil  301  4 
Mar‐08  248  4  7  nil  255  4 
Apr‐08  276  7  8  nil  284  7 
May‐08  261  5  11  1  272  6 
Jun‐08  262  10  8  nil  270  10 
Jul‐08  262  10  8  4  270  14 
Aug‐08  359  5  4  nil  363  05 
Sep‐08  280  6  14  nil  294  06 
Oct‐08  225  1  4  nil  229  01 
Nov‐08  242  5  15  1  257  06 
Dec‐08  285  5  3  nil  288  05 
Jan‐09  270  7  11  nil  281  07 
Feb‐09  258  2  4  nil  262  02 
Mar‐09  276  3  2  nil  278  03 
Apr‐09  255  3  7  1  262  04 
May‐09  197  nil  10  3  207  03 
TOTAL  6329  101  175  23  6504  124 
case  age/ STUDY MARITAL SEXUAL      PMC     EMC  SIMILAR OTHER  SMOK GEN CIRCUMCISION                   SITE INVESTGATION WART DURA HIV CD4+ NO OF TIME RESULT RESPONSE  RESULT  RECURR SIDE
no SEX GROUP STATUS ORIENT ILLNESS STI ING EXAM STATUS VDRL LFT RFT CBC TYPE TION STATUS COUNT APPLIED AT END  AT(WKS) AT 3 MON ENCE EFFECT
79 34/M Group 5 Md HT      +    + NO NO 6 YRS NAD UNCIRCUMCISED INNER LINING PREPUCE NR NV NV NV A 2 MON NR  ‐‐ 1 GRADE‐A 1 NOR NIL LA+
80 46/M Group 5 Md HT     +    + NO NO 10 YRS NAD UNCIRCUMCISED GLANS/ NR NV NV NV A 6WKS R 450 3 GRADE‐B 3 TC    ‐‐‐‐ LA+
81 22/M Group 5 UM HT    ‐     ‐ NO NO   ‐‐ NAD UNCIRCUMCISED INNER LINING PREPUCE NR NV NV NV A 3 MON NR  ‐‐ 2 GRADE‐A 2 NOR NIL LA+
82 39/M Group 5 Md HT    + DENIES NO NO 16  YRS NAD UNCIRCUMCISED GLANS/FRENULUM NR NV NV NV A   3WKS NR  ‐‐ 1 GRADE‐A 1 NOR NIL LA+
83 29/M Group 5 UM HT    ‐    ‐ NO NO 5 YRS NAD CIRCUMCISED PERINEUM/ SHAFT NR NV NV NV KW 1YR NR  ‐‐ 2 GRADE‐A 2 NOR NIL LA+
84 32/M Group 5 Md HT DENIES    + NO NO 8YRS NAD UNCIRCUMCISED INNER LINING PREPUCE NR NV NV NV A 6WKS NR  ‐‐ 2 GRADE‐A 2 NOR NIL LA+
85 43/M Group 5 Md HT    + DENIES NO NO 15 YRS NAD UNCIRCUMCISED INNER LINING PREPUCE NR NV NV NV A 2MON R 300 1 GRADE‐A 1 FF    ‐‐‐‐ LA+
86 49/M Group 5 Md HT    +    + NO NO 20 YRS NAD UNCIRCUMCISED INNER LINING PREPUCE NR NV NV NV PW 4WKS NR  ‐‐ 2 GRADE‐A 2 NOR NIL LA+
87 47/M Group 5 Md HT DENIES     + NO NO 9YRS NAD UNCIRCUMCISED GLANS/FRENULUM NR NV NV NV FP 5WKS NR  ‐‐ 2 GRADE‐A 2 NOR NIL LA+
88 35/M Group 5 Md HT     + DENIES NO NO   ‐‐‐ NAD UNCIRCUMCISED INNER LINING PREPUCE NR NV NV NV A 6 WKS NR  ‐‐ 3 GRADE‐A 3 RO      + LA+
89 27/M Group 5 UM HT    ‐   ‐ NO NO 6 YRS NAD UNCIRCUMCISED INNER LINING PREPUCE NR NV NV NV A 4MON NR  ‐‐ 2 GRADE‐A 2 NOR NIL NIL
90 33/M Group 5 UM HT    ‐     ‐ NO NO 10 YRS NAD UNCIRCUMCISED INNER LINING PREPUCE NR NV NV NV A 12WKS NR  ‐‐ 1 GRADE‐A 1 NOR NIL NIL
91 45/M Group 5 Md HT DENIES      + NO NO   ‐‐ NAD UNCIRCUMCISED INNER LINING PREPUCE NR NV NV NV A 3 MON NR  ‐‐ 2 GRADE‐A 3 NOR NIL LA+
92 29/M Group 5 UM HT       ‐‐    ‐ NO NO 5  YRS NAD UNCIRCUMCISED INNER LINING PREPUCE NR NV NV NV A   6WKS NR  ‐‐ 1 GRADE‐A 1 NOR NIL LA+
93 35/M Group 5 Md HT DENIES DENIES NO NO 15 YRS NAD CIRCUMCISED PERINEUM/ SHAFT NR NV NV NV A 1YR NR  ‐‐ 1 GRADE‐A 1 NOR NIL LA+
94 46/M Group 5 Md HT DENIES     + NO NO 8YRS NAD UNCIRCUMCISED INNER LINING PREPUCE NR NV NV NV A 6WKS R 200 2 GRADE‐A 2 NOR NIL LA+
95 41/M Group 5 Md HT    + DENIES NO NO 15 YRS NAD UNCIRCUMCISED INNER LINING PREPUCE NR NV NV NV A 2MON NR  ‐‐ 3 GRADE‐A 3 NOR NIL NIL
96 35/M Group 5 Md HT DENIES     + NO NO 10 YRS NAD CIRCUMCISED GLANS/FRENULUM NR NV NV NV A 4WKS R 300 2 GRADE‐A 2 NOR NIL NIL
97 25/M Group 5 UM HT DENIES      + NO NO   ‐‐ NAD UNCIRCUMCISED GROIN/PERINEUM/ SHAFT NR NV NV NV KW 8WKS NR  ‐‐ 1 GRADE‐A 1 NOR NIL LA+
98 39/M Group 5 Md HT     + DENIES NO NO   ‐‐‐ NAD UNCIRCUMCISED INNER LINING PREPUCE NR NV NV NV PW 6 WKS NR  ‐‐ 1 GRADE‐A 1 NOR NIL LA+
